Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI)
Terminated
Slow accrual
Other terminated trials from National Cancer Institute (NCI)
Other Breast Cancer trials with similar outcome
Listed as NCT00323063, this PHASE2 trial focuses on Breast Cancer and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 12 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Apr 2023 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Dec 2021 — Sep 2022 [monthly]
Terminated PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Novartis Pharmaceuticals
- Rutgers Cancer Institute of New Jersey
- Rutgers, The State University of New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .